Clinical trial NCT03308604: AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy
Official title: Phase I Study of AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Gynecologic Cancer
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
Collaborators: name: National Cancer Institute, France
First posted: 2017-10-12
Enrollment: 18
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This is a phase 1 clinical trial evaluating the safety, tolerability of escalating doses of AGuIX-NP in combination with radiation and cisplatin in patients with locally advanced cervical cancer. Dose escalation will be conducted using the modified toxicity probability interval (mTPI) method. Three dose levels of intravenous AGuIX nanoparticles will be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2).
Primary purpose: TREATMENT

Brief summary: This is a phase 1 clinical trial evaluating the safety, tolerability of escalating doses of AGuIX-NP in combination with radiation and cisplatin in patients with locally advanced cervical cancer. Dose escalation will be conducted using the modified toxicity probability interval (mTPI) method.

Three dose levels of intravenous AGuIX nanoparticles will be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2).


Eligibility criteria: Inclusion Criteria:

1. Patients with histologically confirmed cancer of the uterine cervix: squamous cell carcinoma or adenocarcinoma stage IB2-IVA according to the International Federation of Gynecology and Obstetrics classification, regardless of the pelvic lymph node stage. No evidence of metastatic disease. Primary staging should include: clinical examination, Pelvic MRI and 18-FDG PET. A coelioscopic para-aortic lymph node staging should be done in patients without para-aortic lymph node uptake to guide radiotherapy fields in the situation of pelvic lymph node metastases. If there is no pelvic lymph node metastases, para-aortic lymph node dissection is optional.
2. ECOG performance status 0-1.
3. Age between 18 - 70 years.
4. Neutrophils \> 2000/mm\^3.
5. Hemoglobin \> 9 g/L after transfusion if necessary.
6. Platelets \> 100,000/mm\^3.
7. Creatinine \< 1.5 upper limit of normal or calculated creatinine clearance (Cockcroft-Gault Formula) ≥ 60 mL/min.
8. Liver function (GOT, GPT, alkaline phosphatase and bilirubin) \< 1.5 upper limit of normal.
9. Cardiovascular: no clinically relevant cardiovascular disease, no congestive heart failure, no symptomatic coronary artery disease, no poorly controlled cardiac arrhythmia, no myocardial infarction within the past year.
10. Gastrointestinal: no active inflammatory bowel disease, no lack of physical integrity of the upper gastrointestinal tract, no malabsorption syndrome.
11. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to initiation of treatment.
12. Proteinuria \< 2 g/L (200mg/dL) and creatinine clearance ≥ 60 mL/min.
13. Signed informed consent after informing the patient.
14. Patient affiliated to a social security regimen or beneficiary of the same.

Exclusion Criteria:

1. Other histological types of cervical cancer than those listed in the inclusion criteria or stage IVB.
2. History of cancer other than basal cell carcinoma within five past years.
3. Prior treatment with radiotherapy, chemotherapy, targeted therapy or immune therapy for cervical cancer or for any cancer within five past years.
4. Prior pelvic radiotherapy or prior surgical treatment for cervical cancer (excluding diagnostic conisation).
5. Pregnancy or breastfeeding.
6. Obesity (Body Mass Index \> 30).
7. History of prior or current psychiatric illness.
8. Nephropathy, regardless of the grade.
9. Peripheral neuropathy ≥ grade 2.
10. Patients with pre-existing hearing impairments.
11. Active infection or other serious underlying pathology that could prevent the patient from receiving the treatment (especially liver or heart conditions).
12. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
13. Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
14. Inclusion in another clinical trial protocol with an experimental molecule (during this study or within 5 years prior to enrollment).
15. Unable to undergo the follow-up required by study for geographical, social or psychological reasons.
16. Contra-indication for Magnetic Resonance Imaging enhanced with gadolinium and/or any contra-indication to the use of cisplatin.
17. History of allergic reaction to cisplatin or other platinum containing compounds.
18. Concurrent administration of yellow fever vaccine.

Primary outcomes:
measure: Maximum Tolerated Dose (MTD)
timeFrame: Day 84 after inclusion
measure: Recommended Phase 2 Dose (RP2D)
timeFrame: Day 84 after inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Pierre-Bénite
country: France
facility: Centre Hospitalier Lyon Sud
state: Rhône
city: Villejuif
country: France
facility: Gustave Roussy
state: Val De Marne
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Cyrus CHARGARI, MD
role: PRINCIPAL_INVESTIGATOR
References: